Khairunnisa Sy
Cancer Chemoprevention Research Center Faculty of Pharmacy, Universitas Gadjah Mada

Published : 2 Documents
Articles

Found 2 Documents
Search

Elettaria cardamomum Distillate Increases Cellular Immunity in Doxorubicin Treated Rats Raksamiharja, Rikat; Sy, Khairunnisa; S, Meirizky Zulharini; Novarina, Annisa; Sasmito, Ediati
Indonesian Journal of Cancer Chemoprevention Vol 3, No 3 (2012)
Publisher : Indonesian Research Gateway

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (4.399 KB)

Abstract

Doxorubicin is one of chemotherapeutic agent used for cancer therapy. However, doxorubicin usage causes some adverse effects, such as lymphocyte, CD4+ and CD8+ cells number.  Therefore,  the  co-chemotherapeutic  agent  is  required  to  reduce  the imunosuppression  effect.  Cardamom  (Elettaria  cardamomum)  contains  terpenoid  1,8  cineol. This  research  aimed  to  know  the  effect  of  Elettaria  cardamomum  distillate  (ECD)  in combination with doxorubicin on Sprague Dawley rat’s hematology profile and the amount of CD4+  and  CD8+  cells.  The  experiment  was  done  for  13  days  using  6  groups  of  rats:  I doxorubicin (dox) 15 mg/kg BW; II dox + ECD5 mg/kg BW; III dox + ECD 50 mg/kg BW; IV dox  +  ECD  100  mg/kg  BW;  V  ECD  100  mg/kg  BW;  VI  control  without  treatment.  The hematology  profile  and  the  amount  of  CD4+  and  CD8+  were  counted  before  and  after treatment  using  flowcytometer.  The  results  show  that  ECD  increases  the  amount  of lymphocyte, white blood, CD4+ and CD8+ cells in dose dependent manner in doxorubicin treated rats. Based on the data, it can be concluded that ECD is potential to be developed as immunostimulant agent for chemotherapy.Keywords: Cardamom (Elettaria cardamomum), immunostimulant, hematology, CD4+, CD8+
Elettaria cardamomum Distillate Increases Cellular Immunity in Doxorubicin Treated Rats Raksamiharja, Rikat; Sy, Khairunnisa; S., Meirizky Zulharini; Novarina, Annisa; Sasmito, Ediati
Indonesian Journal of Cancer Chemoprevention Vol 3, No 3 (2012)
Publisher : Indonesian Society for Cancer Chemoprevention

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14499/indonesianjcanchemoprev3iss3pp437-443

Abstract

Doxorubicin is one of chemotherapeutic agent used for cancer therapy. However, doxorubicin usage causes some adverse effects, such as lymphocyte, CD4+ and CD8+ cells number. Therefore, the co-chemotherapeutic agent is required to reduce the imunosuppression effect. Cardamom (Elettaria cardamomum) contains terpenoid 1,8 cineol. This research aimed to know the effect of Elettaria cardamomum distillate (ECD) in combination with doxorubicin on Sprague Dawley rat’s hematology profile and the amount of CD4+ and CD8+ cells. The experiment was done for 13 days using 6 groups of rats: I doxorubicin (dox) 15 mg/kg BW; II dox + ECD5 mg/kg BW; III dox + ECD 50 mg/kg BW; IV dox + ECD 100 mg/kg BW; V ECD 100 mg/kg BW; VI control without treatment. The hematology profile and the amount of CD4+ and CD8+ were counted before and after treatment using flowcytometer. The results show that ECD increases the amount of lymphocyte, white blood, CD4+ and CD8+ cells in dose dependent manner in doxorubicin treated rats. Based on the data, it can be concluded that ECD is potential to be developed as immunostimulant agent for chemotherapy.Keywords: Cardamom (Elettaria cardamomum), immunostimulant, hematology, CD4+, CD8+